Beck Bode LLC’s Amicus Therapeutics FOLD Stock Holding History

Beck Bode LLC’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-32,792	Closed	-$467K	–	117
2025 Q4	$467K	Buy	+32,792	New	+$322K	0.08%	66

Other funds holding FOLD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

PCM

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Beck Bode LLC's FOLD Position: Q1 2026 in Review

Beck Bode LLC sold out of Amicus Therapeutics (FOLD) in Q1 2026, closing a stake of 32,792 shares — an estimated $467K sold.

Beck Bode LLC first reported a position in FOLD in Q4 2025 and held it in 1 quarter. The position peaked at $467K in Q4 2025. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

Beck Bode LLC reported no remaining Amicus Therapeutics position as of Q1 2026 after selling out during the quarter.
Beck Bode LLC sold 32,792 Amicus Therapeutics shares in Q1 2026, an estimated $467K.
Beck Bode LLC first reported a position in Amicus Therapeutics in Q4 2025 and held it in 1 quarter.
Beck Bode LLC's Amicus Therapeutics position peaked at $467K in Q4 2025.
298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Beck Bode LLC's 13F filing for Q1 2026, filed 7 May 2026.